|
US6541224B2
(en)
|
1996-03-14 |
2003-04-01 |
Human Genome Sciences, Inc. |
Tumor necrosis factor delta polypeptides
|
|
US7217788B2
(en)
|
1996-03-14 |
2007-05-15 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta polypeptides
|
|
US6812327B1
(en)
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
DE69941187D1
(de)
|
1998-06-01 |
2009-09-10 |
Agensys Inc |
Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
|
|
WO2001060397A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20030095967A1
(en)
*
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
AU2001263114A1
(en)
*
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001288301A1
(en)
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
US7189820B2
(en)
|
2001-05-24 |
2007-03-13 |
Human Genome Sciences, Inc. |
Antibodies against tumor necrosis factor delta (APRIL)
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
|
|
US7494646B2
(en)
|
2001-09-06 |
2009-02-24 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
|
WO2003068977A2
(de)
|
2002-02-10 |
2003-08-21 |
Apoxis Sa |
Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
|
|
AU2003221256A1
(en)
*
|
2002-02-21 |
2003-09-09 |
Biogen Idec Ma Inc. |
Use of bcma as an immunoregulatory agent
|
|
BR0313033A
(pt)
*
|
2002-07-25 |
2007-07-10 |
Genentech Inc |
anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
|
|
EP1608730B1
(en)
|
2003-03-28 |
2013-11-06 |
Biogen Idec MA Inc. |
Truncated baff receptors
|
|
ES2537738T3
(es)
*
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
WO2005042009A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for baff antagonists
|
|
BRPI0418766B8
(pt)
|
2004-04-22 |
2021-05-25 |
Agensys Inc |
anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
|
|
CN1786016B
(zh)
*
|
2004-12-09 |
2010-12-29 |
中国人民解放军军事医学科学院基础医学研究所 |
一种人工构建的生物活性分子及其制备方法
|
|
AU2005318086B2
(en)
*
|
2004-12-23 |
2011-07-07 |
Merck Serono Sa |
BCMA polypeptides and uses thereof
|
|
US20080254030A1
(en)
*
|
2005-01-28 |
2008-10-16 |
Charles Mackay |
Use of Baff to Treat Th2-Mediated Conditions
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
KR20080074120A
(ko)
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
WO2007134326A2
(en)
|
2006-05-15 |
2007-11-22 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
|
PT2845866T
(pt)
*
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
|
MD35Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
|
|
MD23Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
|
|
MD36Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
|
|
MD24Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
|
|
EP2488200A4
(en)
*
|
2009-10-14 |
2013-06-12 |
Merck Sharp & Dohme |
APRIL ANTAGONISTS AND METHOD FOR THEIR USE
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
|
TW201425336A
(zh)
*
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
US9688767B2
(en)
|
2013-03-15 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
|
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
|
GB201317929D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
US20150143559A1
(en)
|
2013-11-19 |
2015-05-21 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized a proliferation-inducing ligand gene
|
|
US20170247462A1
(en)
|
2014-07-03 |
2017-08-31 |
Oklahoma Medical Research Foundation |
Treatment of multiple sclerosis and neuromyelitis optica
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
TWI811023B
(zh)
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
JP6901493B2
(ja)
*
|
2015-11-13 |
2021-07-14 |
アメリカ合衆国 |
抗ｂｃｍａポリペプチド及びタンパク質
|
|
US20170145086A1
(en)
|
2015-11-25 |
2017-05-25 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
MA44254A
(fr)
|
2016-02-17 |
2018-12-26 |
Seattle Genetics Inc |
Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
CR20220578A
(es)
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
PE20200010A1
(es)
|
2017-04-03 |
2020-01-06 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
JP7240335B2
(ja)
|
2017-06-20 |
2023-03-15 |
テネオワン， インコーポレイテッド |
抗ｂｃｍａ重鎖のみ抗体
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019220368A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
LT3823990T
(lt)
|
2018-07-20 |
2026-04-10 |
TeneoTwo, Inc. |
Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
BR112022001546A2
(pt)
|
2019-07-30 |
2022-03-22 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
CN116249548A
(zh)
|
2020-05-11 |
2023-06-09 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的方法
|
|
AU2021279035A1
(en)
*
|
2020-05-29 |
2023-02-02 |
Aduro Biotech Holding, Europe B.V. |
Methods of treating IgA nephropathy with an APRIL binding antibody
|
|
IL299027A
(en)
|
2020-06-30 |
2023-02-01 |
Teneobio Inc |
Multispecific antibodies that bind BCMA
|
|
WO2022175255A2
(en)
|
2021-02-16 |
2022-08-25 |
Janssen Pharmaceutica Nv |
Trispecific antibody targeting bcma, gprc5d, and cd3
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
CA3228678A1
(en)
|
2021-08-11 |
2023-02-16 |
Amato J. Giaccia |
Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
|
|
EP4426437A4
(en)
|
2021-11-03 |
2025-09-17 |
Janssen Biotech Inc |
METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
US20250262300A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026061495A1
(zh)
*
|
2024-09-20 |
2026-03-26 |
长春金赛药业有限责任公司 |
一种阻断BAFF、APRIL作用其受体的Fc融合蛋白
|